GMP Cell Banking Service Market

GMP Cell Banking Service Market Outlook (2024 to 2034)

The global GMP cell banking service market is expected to garner a revenue of around US$ 882.1 million in 2024. Market assessment on a global scale reveals the demand for GMP cell banking services to rise at a healthy 13.5% CAGR from 2024 to 2034. The assessment report further predicted a valuation of US$ 3,123.5 million by 2034 end.

Key Market Growth Drivers

• Fast-developing and expanding biopharmaceutical sectors after the pandemic have spawned a lucrative growth of GMP cell banking services worldwide.
• The rising complexity of cell-based therapies has surged the requirement for expert cell banking for accelerated drug discovery.
• Reputable GMP cell banking services that can accommodate global distribution and regulatory requirements are gaining more traction these days.
• The commercialization of biopharmaceutical manufacturing facilities in recent years has also altered the GMP cell banking service market dynamics.

Report Attributes	Details
Estimated Market Value (2024)	US$ 882.1 million
Forecast Market Value (2034)	US$ 3,123.5 million
Global Market Growth Rate (2024 to 2034)	13.5% CAGR
Microbial Segment Growth Rate (2024 to 2034)	14.3%
Contract Manufacturing Organizations Segment Growth Rate (2024 to 2034)	13.9%
North America Market Share (2024)	47.9%
Western Europe Market Share (2024)	28.6%
Key Companies Profiled	WuXi AppTec Charles River Laboratories Eurofins Scientific Merck KGaA Lonza SGS Life Sciences Ltd. ViruSure Austrianova Goodwin Biotechnology Paragon Bioservices Bio Reliance Sartorius Thermo Fisher BSL Bioservice Cleancells Covance

Which Factors Drive the Global Surge in GMP Cell Banking Service Demand?

“Pharmaceutical Industries are at the Helm of Cell Line Banking Services Market Growth”

Pharmaceutical firms outsource GMP-compliant cell banking services to store and deliver master and working cell banks safely. At the moment, the market for biologics, cell therapies, and gene therapies is expanding fast, and there has been a steep rise in cell banking systems worldwide.

The increasing variety of cell-based therapeutics, such as personalized medicine and regenerative therapies, has increased the demand for cell banks in the pharmaceutical industry. GMP cell banking and storage services that are tailored to the specific requirements of the biopharmaceutical industry are the cornerstones of the research and development of new treatments.

“Diversification and Specialization of Biological Sample Storage is the Key to Growth”

There is a growing need for GMP cell banking services because of the rising demand for clinical trials and the emerging trend for cell-based medicines in the recent past. As GMP-compliant cell banks have become necessary for biopharmaceutical businesses undertaking clinical trials, the overall market is expected to strengthen fast in the coming days.

In recent years, specialized GMP cell banking requirements have also surged due to ongoing improvements in cell line creation for medicinal purposes. Similarly, GMP-compliant banking services are essential for maintaining the integrity and unique qualities of new cell lines that researchers and developers are investigating for vaccination development.

Which Factors Present Challenges to the Expansion of the GMP Cell Banking Service Market?

“Energy Consumption, Contamination, and Outmoded Cell Lines Limit the Market Expansion”

Cell line contamination at GMP cell banks is a significant concern, given that diverse types of cell lines and their variants are stored at such organizations. Maintaining the stability of cell lines over time also entails higher energy consumption, which can add up to the cost of end products developed utilizing commonly available cell lines.

The emergence of rare and novel variants of pathogens has resulted in biopharmaceutical companies often requiring unique cell lines based on the specific characteristics of drugs to be developed. In such situations, the end users go for in-house development of new cell lines rather than depending on cell banks, that are mostly a repository of outmoded cell lines.

Country-wise Insights

Country	Regional Market CAGR (2024 to 2034)
United States	13.1%
Canada	12.7%
Germany	12%
United Kingdom	10.7%

Which Factors Position the United States as a Thriving Market for GMP Cell Banking Service?

“Strict Regulations by USFDA have Accelerated the GMP Cell Banking Services Advancement”

The market in North America is estimated to be valued at US$ 423 million in 2024. The United States dominates the market in North America with an estimated CAGR of 13.1% through the forecast years.

Good manufacturing practices or GMP rules are mandatory in the United States due to the strict regulatory environment in the biopharmaceutical and cell therapy sectors. So, the regional market is up there to adopt cGMP cell banking and storage services to guarantee adherence to FDA legal criteria.

Why has the Demand for GMP Cell Banking Services in Canada Skyrocketed in the Recent Year?

“Canada Players Improving Their Cellular Storage Solutions to Compete with Global Players”

Canada holds around 22.8% of the good manufacturing practice cell banking services market in North America. Over the projection years, it is expected to grow at an annual growth rate of 12.7% from 2024 to 2034.

GMP cell banking services are strengthening in Canada with the growing acceptability and use of cell therapy treatments in the country. Players in Canada are also entering the global competition by offering records and procedures that satisfy global health authorities' standards.

Why Germany Remains the Lucrative Market for Quality Controlled Cell Banking Services?

“Emerging Biopharmaceutical Research Institutes are Rising Demand in Germany”

Germany contributes to almost one-third of cell storage and retrieval requirements in Europe. With an estimated market valuation of US$ 78 million in 2024, the GMP cell line maintenance market in Germany is forecast to progress at a 12% CAGR through 2034.

Regional players who can handle the logistical issues associated with cross-border cell banking are expected to remain crucial partners for many international corporations located in Germany. Opportunities for German cell banking service providers are also expected to emerge more from the growing trend of outsourcing several stages of biopharmaceutical research to adjacent European countries.

Why is the United Kingdom Dominating the Global GMP Cell Banking Service Market in Europe?

“The United Kingdom Iodine Industry Sets the Standard with Cutting-Edge Extraction”

GMP cell-line banking services in the United Kingdom are estimated to create a revenue of US$ 63 million in 2024. This regional market is further predicted to witness a growth rate of 10.7% between 2024 and 2034.

The need for GMP cell banking services has been fueled in the United Kingdom with the rapidly growing market for gene and cell treatments after the pandemic outbreak in 2020. This regional market has witnessed tremendous growth in the last two years, driven by ground-breaking discoveries and approvals for the discovery of innovative medicines.

Category-wise Insights

Why Mammalian Cells Rule the Global Biopreservation Services Market?

“Resemblance to Human Protein Makes Mammalian Cells an Ideal Category for Banking Service Providers”

The revenue accumulated by service providers only from the storage of mammalian cells is estimated to be around US$ 592.5 million in 2024. Over the projected period, this segment is projected to grow at a 13.4% rate per year.

Mammalian cells, in particular Chinese hamster ovary (CHO) cells, can produce proteins that bear a striking resemblance to human proteins. The pharmaceutical industry's rising need for complicated biologics such as monoclonal antibodies, vaccines, and cell treatments is expected to propel the mammalian cell banking segment to new heights.

Which Cell Type Segment is Expected to Create More Opportunities for Market Players?

“Diverse Applications of Microbial Cells Makes its Preservation more Economical”

According to market projections, the microbial cell segment is expected to follow a higher CAGR of 14.3% through the forecast years.

Demand for microbial cell line banking is higher among specialist biopharmaceutical companies as the research for new medicines is frequently carried out using microbial systems like yeast or bacteria. Moreover, microbial systems are employed for the synthesis of enzymes, recombinant proteins, and vaccines which is expected to drive this segment further.

Why Biopharmaceutical Companies Hold Sway over Whole GMP Cell Banking Services Market?

“Efficiency and Quality Assurance Obligations of Biopharmaceutical Companies is at the Heart”

Based on a survey of different end-use verticals for GMP cell banking service providers, the biopharmaceutical companies contribute to more than 70% of the total demand. The analysis of the numbers pegs the CAGR for this segment at 13.3% during the period between 2024 and 2034.

GMP cell banking services are essential for all biopharmaceutical companies to guarantee the consistency, quality, and legal compliance of the cell lines utilized in the creation of novel drugs. In addition to this, GMP cell banking services shorten the time needed for the development and commercialization of treatments by offering ready-to-use and compliant cell banks.

Why Contract Manufacturing Companies are Requiring GMP Cell Banking Services Nowadays?

“Biopharmaceutical Companies are Outsourcing to CMOs More These Days”

According to market analysis, contract manufacturing companies' demand for GMP cell banking services is expected to rise at a 13.9% CAGR through 2034.

Biopharmaceutical firms outsourcing particular phases of the production process to contract manufacturing organizations (CMOs) is an emerging trend these days. Biopharmaceutical businesses also obtain infrastructure and knowledge at a reasonable cost by working with CMOs, as building up internal cell line banking capabilities can be resource-intensive.

Competitive Landscape

As per the industry survey report, though many market players are competing at present, the scattered presence of these companies is what makes it diversified. By prioritizing regulatory compliance, established service providers build industry confidence and trustworthiness and control a sizable share of the global market. However, some new market players who are providing scalable and adaptable solutions to meet the various needs of gene therapy and cell therapy researchers are observed to be growing fast against even leading market players.

Recent Developments by the GMP Cell Banking Service Providers

In April 2022, FUJIFILM Corporation acquired Atara Biotherapeutics Incorporate, which is an exclusive cell therapy manufacturing company in the United States. Through this acquisition, FUJIFILM Co., a leading contract development and manufacturing organization, also announced the production of both clinical and commercial cell therapies, such as allogeneic T-cell and CAR T immunotherapies.

In June 2021, Mecart created a Grade C cell banking cleanroom with its proficiency in creating biotech cleanrooms. All of the equipment required for cell banking operations is located in the grade C cleanroom area. The firm itself employs virus-like particles (VLP) to create vaccines. Production of cell banks must adhere to the cGMP cleanroom and manufacturing specifications mandated by regulating agencies like the US FDA or Health Canada.

Segmentation of GMP Cell Banking Service Market Research

• By Cell Type:

  • Mammalian
  • Microbial
  • Insect
  • Yeast
  • Avian
  • Stem
  • Others

• By End User:

  • Biopharmaceutical Companies
  • Contract Manufacturing Organizations

• By Region:

  • North America
  • Europe
  • Latin America
  • East Asia
  • South Asia & Oceania
  • The Middle East & Africa